Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Scott Shay

Vascular & Interventional Radiology Dededo, GU Medical Doctor

NPI 1720175847 CMS profile 213877

133 Route 3, Guam Regional Medical City, Dededo, GU 96929

Open in the dashboard

General payments

$4,351

18 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Shay of Dededo, GU is reported in the CMS Open Payments database as having received $4,351 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,874 9
2024 General $218 2
2023 General $227 5
2021 General $32 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Shay
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Scott Shay were reported at $3,874. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Scott Shay Vascular & Interventional Radiology median Middle half National median
2019 $0 $422 $125–$1,555 $163
2020 $0 $200 $68–$652 $114
2021 $32 $280 $99–$866 $132
2022 $0 $433 $137–$1,497 $149
2023 $227 $506 $152–$2,019 $160
2024 $218 $556 $175–$1,930 $164
2025 $3,874 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Stryker Corporation $3,810 7 payments
  2. AngioDynamics, Inc. $214 4 payments
  3. Abbott Laboratories $196 4 payments
  4. Abiomed $82 1 payment
  5. Cardiovascular Systems Inc. $49 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $3,521 3 payments
  2. Food and Beverage $830 15 payments
Products named General payments · program years 2021–2025
  1. EVOLVE $3,729 6 payments
  2. AURYON LASER SYSTEM 100-120 VAC Pad $200 3 payments
  3. PROCLAIM Neuromodulation $100 2 payments
  4. PROCLAIM Neuromodulation $96 2 payments
  5. Impella $82 1 payment
  6. SURPASS EVOLVE $81 1 payment
  7. Diamondback Peripheral $49 2 payments
  8. Auryon Laser System 100-120 Vac Et $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 166 billing codes

Paid by Medicare

$1,290,006

Of which drugs: $5,585

Medicare patients

540

Average age 70

Services billed

21,082

242 women, 298 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 66%
Heart failure 48%
Ischemic heart disease 48%
Arthritis 30%
Atrial fibrillation 28%
COPD 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, alteplase recombinant, 1 mg J2997 Office 27 53 $3,504
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 210 17,556 $1,606
Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 Office 138 280 $281
Injection, heparin sodium, per 1000 units J1644 Office 103 798 $139
Injection, cefazolin sodium, 500 mg J0690 Office 11 23 $14
Injection, fentanyl citrate, 0.1 mg J3010 Office 13 15 $9
Injection, midazolam hydrochloride, per 1 mg J2250 Office 14 17 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Guam

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record